The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
Caribou, the genome engineering company spun off from Jennifer Doudna’s CRISPR lab at Berkeley three years ago, announced that it has agreed to a cross-licensing deal with DuPont, the industrial-chemicals company. Intellectual property will be shared between the companies in a variety of fields; the deal also includes a multi-year research collaboration and some investments for Caribou.
“Both companies control pretty broad CRISPR-Cas genome engineering technology portfolios,” explains Caribou CEO Rachel Haurwitz, who was on the 2014 FORBES 30 Under 30 list for Science & Healthcare. “It was clear to us that DuPont was going to be a really important, valuable partner.”
Each company is getting some exclusive and some nonexclusive rights to the other’s intellectual property. From Caribou, DuPont gets exclusive access to technology for working with certain agricultural crops and nonexclusive access to some of Caribou’s other ideas related to agriculture and industrial biotech. And Caribou is able to license DuPont’s CRISPR technology for human and animal therapeutics, more industrial biotech and some other fields, on both exclusive and nonexclusive bases.
Read full, original post: Caribou, A CRISPR Genome-Editing Company, Is Going To Share Ideas With DuPont
